Cargando…
Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study
Background: Monopolar radiofrequency ablation is currently deemed an exotic treatment option for benign thyroid nodules in many central European countries. The aim of this study was to evaluate prospectively the safety and efficacy of this method in a large patient cohort following its introduction...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905420/ https://www.ncbi.nlm.nih.gov/pubmed/29490593 http://dx.doi.org/10.1089/thy.2017.0547 |
_version_ | 1783315261307224064 |
---|---|
author | Dobnig, Harald Amrein, Karin |
author_facet | Dobnig, Harald Amrein, Karin |
author_sort | Dobnig, Harald |
collection | PubMed |
description | Background: Monopolar radiofrequency ablation is currently deemed an exotic treatment option for benign thyroid nodules in many central European countries. The aim of this study was to evaluate prospectively the safety and efficacy of this method in a large patient cohort following its introduction in Austria. Methods: Peri- and post-interventional complications were analyzed for 277 patients. Efficacy was determined for 300 and 154 nodules at 3 and 12 months post treatment, respectively. All treatments were performed with an internally cooled 18G radiofrequency electrode using a free-hand, “moving-shot” technique following subcutaneous and local perithyroidal anesthesia. Results: Mean patient age (SD) was 52 ± 12.9 years (75% female), and overall mean baseline nodule volume (SD) was 13.8 ± 15.9 mL. Nodules were visible in 62.8% of patients, 40% had a symptom score ≥4 on a 10-point visual analogue scale, and 14.4% had hyperthyroidism. Mean overall nodule volume reduction rates (VRR) at 3 and 12 months were 68 ± 16% and 82 ± 13%, respectively (p < 0.001). At 12 months, 81% of nodules exhibited a VRR of ≥70%, with 10%, 6%, and 2% of nodules showing VRRs of 60–70%, 50–60%, and ≤50%, respectively. Subgroup analysis according to baseline nodule size (≤10 mL to >30 mL) or baseline nodule composition (solid, mixed, cystic) revealed significantly higher VRRs for smaller and cystic nodules. Moreover, nodule shrinkage was accompanied by significantly improved symptom and cosmetic scores after 3 and 12 months (p < 0.001). Of 32 hyperthyroid patients, 27 (84%) were euthyroid, four had subclinical hyperthyroidism, and one had subclinical hypothyroidism at last follow-up. Post-procedural complications were absent in 83% of patients, minimal in 12.9%, moderate and reversible in 3.2% (1.8% voice change, 0.7% hyperthyroidism, 0.3% wound infection treated with antibiotics, 0.3% epifascial hematoma), and irreversible in 0.7% (one case with hypothyroidism and one with a wound infection treated by surgery). Conclusions: It is concluded that a single treatment course with monopolar radiofrequency ablation is both safe and highly effective in terms of nodule volume reduction, relief of local symptoms, and (in patients with hyperthyroidism) restoration of euthyroid function. In no case was a prescription of thyroid medication required among those patients who were euthyroid at baseline. |
format | Online Article Text |
id | pubmed-5905420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59054202018-04-19 Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study Dobnig, Harald Amrein, Karin Thyroid Thyroid Cancer and Nodules Background: Monopolar radiofrequency ablation is currently deemed an exotic treatment option for benign thyroid nodules in many central European countries. The aim of this study was to evaluate prospectively the safety and efficacy of this method in a large patient cohort following its introduction in Austria. Methods: Peri- and post-interventional complications were analyzed for 277 patients. Efficacy was determined for 300 and 154 nodules at 3 and 12 months post treatment, respectively. All treatments were performed with an internally cooled 18G radiofrequency electrode using a free-hand, “moving-shot” technique following subcutaneous and local perithyroidal anesthesia. Results: Mean patient age (SD) was 52 ± 12.9 years (75% female), and overall mean baseline nodule volume (SD) was 13.8 ± 15.9 mL. Nodules were visible in 62.8% of patients, 40% had a symptom score ≥4 on a 10-point visual analogue scale, and 14.4% had hyperthyroidism. Mean overall nodule volume reduction rates (VRR) at 3 and 12 months were 68 ± 16% and 82 ± 13%, respectively (p < 0.001). At 12 months, 81% of nodules exhibited a VRR of ≥70%, with 10%, 6%, and 2% of nodules showing VRRs of 60–70%, 50–60%, and ≤50%, respectively. Subgroup analysis according to baseline nodule size (≤10 mL to >30 mL) or baseline nodule composition (solid, mixed, cystic) revealed significantly higher VRRs for smaller and cystic nodules. Moreover, nodule shrinkage was accompanied by significantly improved symptom and cosmetic scores after 3 and 12 months (p < 0.001). Of 32 hyperthyroid patients, 27 (84%) were euthyroid, four had subclinical hyperthyroidism, and one had subclinical hypothyroidism at last follow-up. Post-procedural complications were absent in 83% of patients, minimal in 12.9%, moderate and reversible in 3.2% (1.8% voice change, 0.7% hyperthyroidism, 0.3% wound infection treated with antibiotics, 0.3% epifascial hematoma), and irreversible in 0.7% (one case with hypothyroidism and one with a wound infection treated by surgery). Conclusions: It is concluded that a single treatment course with monopolar radiofrequency ablation is both safe and highly effective in terms of nodule volume reduction, relief of local symptoms, and (in patients with hyperthyroidism) restoration of euthyroid function. In no case was a prescription of thyroid medication required among those patients who were euthyroid at baseline. Mary Ann Liebert, Inc. 2018-04-01 2018-04-01 /pmc/articles/PMC5905420/ /pubmed/29490593 http://dx.doi.org/10.1089/thy.2017.0547 Text en © Harald Dobnig and Karin Amrein 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Thyroid Cancer and Nodules Dobnig, Harald Amrein, Karin Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study |
title | Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study |
title_full | Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study |
title_fullStr | Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study |
title_full_unstemmed | Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study |
title_short | Monopolar Radiofrequency Ablation of Thyroid Nodules: A Prospective Austrian Single-Center Study |
title_sort | monopolar radiofrequency ablation of thyroid nodules: a prospective austrian single-center study |
topic | Thyroid Cancer and Nodules |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905420/ https://www.ncbi.nlm.nih.gov/pubmed/29490593 http://dx.doi.org/10.1089/thy.2017.0547 |
work_keys_str_mv | AT dobnigharald monopolarradiofrequencyablationofthyroidnodulesaprospectiveaustriansinglecenterstudy AT amreinkarin monopolarradiofrequencyablationofthyroidnodulesaprospectiveaustriansinglecenterstudy |